1,4,7,10-tetraazacyclododecane

We are 1,4,7,10-tetraazacyclododecane CAS:294-90-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1,4,7,10-tetraazacyclododecane
CAS.NO:294-90-6
Synonyms:1,4,7,10-tetraazacyclododecane
Cyclen
1,4,7,10-Tetrazacyclododecane
1,4,7,10-Tetraazacyclododecane
1,4,7,12-tetraazacyclodedecane
Molecular Formula:C8H20N4
Molecular Weight:172.27100
 
Physical and Chemical Properties:
Density:0.874
Melting point:110-113ºC
Boiling point:283.8ºC
Flash point:129.5ºC
 
Specification:
Appearance:White to light yellow crystalline powder
Assay:98.0%-102.0%
Melting point:108-114ºC
Residue on ignition:≤0.5%
Hydrate constituent:≤0.5%
Heavy metals:≤20ppm
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Gadobutrol

1,4,7,10-tetraazacyclododecane


Related News: Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.2,4-Dichloro-5-nitrophenol CAS:39489-77-5 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.1,12-Dodecanediol CAS:5675-51-4 In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.quinolinic acid In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA’s concerns.

Related Products
Product Name
(5α)-Androst-16-en-3-one View Details
Aminoacetonitrile Hydrochloride View Details
BOC-ALANINE-1-HYDROXYSUCCINIMIDE ESTER View Details
1-(Cyclopropylcarbonyl)piperazine manufacturer 2-Chloro-4-(Methylsulfonyl)Benzoic Acid manufacturer 3-Fluoropyridine manufacturer (S)-3-Fluoropyrrolidine hydrochloride manufacturer propan-2-yl (2S)-2-[[(2,3,4,5,6-pentafluorophenoxy)-phenoxyphosphoryl]amino]propanoate manufacturer